Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

• Rajshekhar Chakraborty,
• Heloise Cheruvalath,
• Anannya Patwari,
• Aniko Szabo,
• Carolina Schinke,
• Binod Dhakal,
• Suzanne Lentzsch,
• Anita D’Souza,
• Ghulam Rehman Mohyuddin,
• Kelley Julian,
• Shonali Midha,
• Patrick Costello,
• Martin Kaiser,
• Melissa Ng Liet Hing,
• Simon J. Harrison,
• Edward R. Scheffer Cliff,
• Meera Mohan

Affiliations

Rajshekhar Chakraborty

Columbia University Irving Medical Center

Heloise Cheruvalath

Medical College of Wisconsin

Anannya Patwari

Medical College of Wisconsin

Aniko Szabo

Medical College of Wisconsin

Carolina Schinke

University of Arkansas for Medical Sciences

Binod Dhakal

Medical College of Wisconsin

Suzanne Lentzsch

Columbia University Irving Medical Center

Anita D’Souza

Medical College of Wisconsin

Ghulam Rehman Mohyuddin

Huntsman Cancer Center, University of Utah

Kelley Julian

Huntsman Cancer Center, University of Utah

Shonali Midha

Dana Farber Cancer Institute and Harvard Medical School

Patrick Costello

Dana Farber Cancer Institute and Harvard Medical School

Martin Kaiser

The Institute of Cancer Research

Melissa Ng Liet Hing

Sir Peter MacCallum Department of Oncology, University of Melbourne

Simon J. Harrison

Sir Peter MacCallum Department of Oncology, University of Melbourne

Edward R. Scheffer Cliff

Sir Peter MacCallum Department of Oncology, University of Melbourne

Meera Mohan

Medical College of Wisconsin